Flecainide acetate for the treatment of atrial and ventricular arrhythmias

Bibliography

• Hudak JM, Banitt EH, Schmid JR. Discovery and development of flecainide. Am J Cardiol 1984;53:17B-20B
   Google Scholar
• Tamargo J, Capucci A, Mabo P. Safety of flecainide. Drug Saf 2012;35:273-89
   Google Scholar
• Seipel L, Abendroth RR, Breithardt G. Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl). Z Kardiol 1981;70:524-9
   Google Scholar
• Bluschke V, Breithardt G, Abendroth RR, Effect of flecainide on chronic ventricular arrhythmias (author's transl). Z Kardiol 1982;71:284-8
   Google Scholar
• Breithardt G, Borggrefe M, Yeh HL, Electrophysiological effects of flecainide on stimulus-inducible ventricular tachycardia. Z Kardiol 1982;71:278-83
   Google Scholar
• Hoffmeister HM, Hepp A, Seipel L. Modification of hemodynamics by intravenous administration of flecainide. Z Kardiol 1986;75:176-81
   Google Scholar
• Hoffmeister HM, Hormann HP, Beyer M, Negative inotropic effect of flecainide on the post-ischemic heart with limited contractile function. Z Kardiol 1990;79:189-92
   Google Scholar
• Kuhlkamp V, Schmid F, Risler T, Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. Int J Cardiol 1991;31:65-9
   Google Scholar
• Lederman SN, Wenger TL, Bolster DE, Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. J Cardiovasc Pharmacol 1989;13:541-6
   Google Scholar
• Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986;8:607-15
   PubMed Web of Science ®Google Scholar
• Anderson JL, Stewart JR, Perry BA, Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 1981;305:473-7
   PubMed Web of Science ®Google Scholar
• Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. Circulation 1983;67:1117-23
   PubMed Web of Science ®Google Scholar
• Borgeat A, Goy JJ, Maendly R, Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58(6):496-8
   PubMed Web of Science ®Google Scholar
• Brembilla-Perrot B, Amor M, Auque F, Effect of flecainide on left ventricular ejection fraction. Eur Heart J 1987;8:754-61
   Google Scholar
• Crijns HJ, van Wijk LM, van Gilst WH, Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988;9:634-8
   Google Scholar
• Dubner SJ, Elencwajg BD, Palma S, Efficacy of flecainide in the management of ventricular arrhythmias: comparative study with amiodarone. Am Heart J 1985;109:523-8
   Google Scholar
• Henze E, Roth J, Haerer W, Long term inotropic effects of flecainide and propafenone. Eur J Nucl Med 1988;13:568-71
   Google Scholar
• Hodges M, Haugland JM, Granrud G, Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent. Circulation 1982;65:879-85
   PubMedGoogle Scholar
• Hodges M, Salerno DM, Granrud G. Flecainide versus quinidine: results of a multicenter trial. Am J Cardiol 1984;53:66B-71B
   Google Scholar
• Josephson MA, Kaul S, Hopkins J, Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. Am Heart J 1985;109:41-5
   PubMed Web of Science ®Google Scholar
• Schmidt G, Goedel-Meinen L, Jahns G, Long term efficacy of class I antiarrhythmic agents and amiodarone in patients with malignant ventricular arrhythmias. Drugs 1985;29:37-46
   Google Scholar
• Stroobandt R, Andries E, van Mieghem W, Efficacy and tolerance of intravenous flecainide in patients with chronic high frequency ventricular arrhythmias. Eur Heart J 1984;5:876-82
   Google Scholar
• Anderson JL, Gilbert EM, Alpert BL, Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-70
   PubMed Web of Science ®Google Scholar
• Neuss H, Schlepper M. Long-term efficacy and safety of flecainide for supraventricular tachycardia. Am J Cardiol 1988;62:56D-61D
   Google Scholar
• Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 1992;70:56A-60A; discussion 60A-61A
   Google Scholar
• Aliot E, Capucci A, Crijns HJ, Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 2011;13:161-73
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members. Camm AJ, Lip GY, De Caterina R, 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21):2719-47
   Google Scholar
• Akhtar M, Breithardt G, Camm AJ, CAST and beyond. Implications of the cardiac arrhythmia suppression trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1990;81:1123-7
   Google Scholar
• Wann LS, Curtis AB, January CT, 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011;8:157-76
   PubMed Web of Science ®Google Scholar
• European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Kirchhof PF, Fabritz CL, Franz MR. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. Circulation 1998;97:2567-74
   PubMed Web of Science ®Google Scholar
• Wang JA, Lau CP, Tai YT, Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease. Clin Cardiol 1995;18:140-4
   Google Scholar
• Doki K, Homma M, Kuga K, Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 2009;68:89-96
   PubMed Web of Science ®Google Scholar
• Roden DM, Woosley RL. Drug therapy: flecainide. N Engl J Med 1986;315:36-41
   PubMed Web of Science ®Google Scholar
• Anno T, Hondeghem LM. Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circ Res 1990;66:789-803
   PubMed Web of Science ®Google Scholar
• Follmer CH, Colatsky TJ. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990;82:289-93
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Gomez R, Pharmacology of cardiac potassium channels. Cardiovasc Res 2004;62:9-33
   PubMed Web of Science ®Google Scholar
• Boriani G, Biffi M, Capucci A, Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol 1998;21:2470-4
   PubMed Web of Science ®Google Scholar
• Capucci A, Lenzi T, Boriani G, Effectiveness of loading oral flecainide for converting recent onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72
   PubMed Web of Science ®Google Scholar
• Donovan KD, Dobb GJ, Coombs LJ, Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 1992;70:50A-5A
   Google Scholar
• Donovan KD, Power BM, Hockings BE, Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995;75:693-7
   PubMed Web of Science ®Google Scholar
• Romano S, Fattore L, Toscano G, Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation. Ital Heart J Suppl 2001;2:41-5
   Google Scholar
• Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86:950-3
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Andresen D, Bosch R, Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012;380:238-46
   Google Scholar
• Steinbeck G, Doliwa R, Bach P. Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents? Dtsch Med Wochenschr 1988;113:1867-71
   Google Scholar
• Anderson JL, Gilbert EM, Alpert BL, Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-70
   PubMed Web of Science ®Google Scholar
• van Wijk LM, den Heijer P, Crijns HJ, Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 1989;13:32-6
   Google Scholar
• Van Gelder IC, Crijns HJ, Van Gilst WH, Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-21
   PubMedGoogle Scholar
• Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 1991;67:713-17
   PubMedGoogle Scholar
• Carunchio A, Fera MS, Mazza A, A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation. G Ital Cardiol 1995;25:51-68
   Google Scholar
• Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 1996;77:66A-71A
   PubMed Web of Science ®Google Scholar
• Chimienti M, Cullen MT Jr, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 1995;16:1943-51
   Google Scholar
• Naccarelli GV, Dorian P, Hohnloser SH, Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996;77:53A-9A
   PubMed Web of Science ®Google Scholar
• Gulizia M, Mangiameli S, Orazi S, PITAGORA Study Investigators. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: a Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J 2008;155:100-7. 107.e1
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;70:3A-9A; discussion A-10A
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012;5:CD005049
   Google Scholar
• Turco P, De Simone A, La Rocca V, Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. Pacing Clin Electrophysiol 2005;28(Suppl 1):S124-7
   Google Scholar
• Reid PR, Griffith LSC, Platia EV, Ord SE. Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death. Am J Cardiol 1984;53:108B-IIB
   Google Scholar
• Anderson JL, Lutz JR, Allison SB. Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia. J Am Coll Cardiol 1983;2:105-14
   PubMed Web of Science ®Google Scholar
• van Wijk LM, Crijns HJ, Kingma HJ, Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation. J Cardiovasc Pharmacol 1990;15:884-91
   Google Scholar
• Herre JM, Titus C, Oeff M, Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Ann Intern Med 1990;113:671-6
   Google Scholar
• van der Werf C, Kannankeril PJ, Sacher F, Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011;57:2244-54
   PubMed Web of Science ®Google Scholar
• Watanabe H, Chopra N, Laver D, Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009;15:380-3
   PubMed Web of Science ®Google Scholar
• Pflaumer A, Davis AM. Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ 2012;21:96-100
   Google Scholar
• Alboni P, Botto GL, Baldi N, Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351:2384-91
   PubMed Web of Science ®Google Scholar
• McNamara RL, Tamariz LJ, Segal JB, Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003;139:1018-33
   PubMed Web of Science ®Google Scholar
• Wehling M. Meta-analysis of flecainide safety in patients with supraventricular arrhythmias. Arzneimittelforschung 2002;52:507-14
   Google Scholar
• Andersen SS, Hansen ML, Gislason GH, Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace 2009;11:886-91
   Google Scholar
• Lewis GP, Holtzman JL. Interaction of flecainide with digoxin and propranolol. Am J Cardiol 1984;53:52B-7B
   Google Scholar
• Kennedy HL, Brooks MM, Barker AH, Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 1994;74:674-80
   PubMed Web of Science ®Google Scholar
• Cosedis Nielsen J, Johannessen A, Raatikainen P, Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012;367:1587-95
   PubMed Web of Science ®Google Scholar
• Bash LD, Buono JL, Davies GM, Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-79
   PubMedGoogle Scholar
• Donovan KD, Dobb GJ, Coombs LJ, Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991;67:137-41
   PubMed Web of Science ®Google Scholar
• Reisinger J, Gatterer E, Lang W, Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-24
   PubMed Web of Science ®Google Scholar